Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II).

about

Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II).

Item

http://www.wikidata.org/entity/Q47910619

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II).

@en

Integrative tumor board: metastatic renal cell carcinoma: medical oncology

@nl

type

Item

label

Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II).

@en

Integrative tumor board: metastatic renal cell carcinoma: medical oncology

@nl

prefLabel

Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II).

@en

Integrative tumor board: metastatic renal cell carcinoma: medical oncology

@nl

P1476

Integrative tumor board: metastatic renal cell carcinoma: medical oncology (II).

@en

P2093

Hardev Pandha

http://www.w3.org/2001/XMLSchema#string

P2860

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer.

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Natural history of chronic renal insufficiency after partial and radical nephrectomy.

Mode of presentation of renal cell carcinoma provides prognostic information.

Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma.

Prognostic factors in renal cell carcinoma.

Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study

Spontaneous regression of metastatic renal cell carcinoma.

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

P304

29-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1534735404262986

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15035872

http://www.w3.org/2001/XMLSchema#string